FDA Updates: Real-Life Proof for Medical Gadgets
Published Date: 12/18/2025
Notice
Summary
The FDA just released updated rules on how real-world data can help approve medical devices faster and smarter. This affects medical device makers and FDA staff by giving clearer, better ways to use everyday health info for decisions. The new guidance starts December 18, 2025, aiming to speed up approvals without extra costs.
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Clarifies use of real‑world data
If you are a medical device sponsor or manufacturer, FDA issued final guidance on December 18, 2025 that explains how FDA evaluates real‑world data (RWD) to determine whether they are good enough to generate real‑world evidence (RWE) for regulatory decision‑making. The guidance updates and expands the 2017 RWE guidance and gives recommendations on when RWD sources and study approaches are relevant and reliable.
EUA and CLIA data usability clarified
The guidance provides additional clarity about using clinical data collected from devices authorized under an Emergency Use Authorization (EUA) and describes what types of information could be applicable to support Clinical Laboratory Improvement Amendments (CLIA) determinations, such as a Waiver by Application. This helps sponsors know when EUA‑collected data might be acceptable for certain regulatory or CLIA decisions.
60‑day operational transition period
FDA recognizes that the Agency and industry may need up to 60 days to operationalize the recommendations in this final guidance. For submissions pending after publication on December 18, 2025, and for submissions received within 60 days following that date, FDA generally does not expect sponsors to already include the newly recommended information, though FDA will review any such information if it is submitted.
No new paperwork collections required
The guidance states it contains no new collection of information under the Paperwork Reduction Act and instead refers to previously approved FDA collections with listed OMB control numbers. That means the guidance itself does not add new PRA reporting requirements.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2025-23251, Submission for OMB Review; 30-Day Comment Request; Special Volunteer and Guest Researcher Assignment (Office of Intramural Research, Office of the Director)
The NIH is asking for a 30-day public comment on their request to keep collecting info from special volunteers and guest researchers. This affects people who work or volunteer in NIH research programs and won’t cost anyone extra money. They want to make sure their forms stay approved and easy to use, so the research keeps running smoothly.
Next: 2025-23255, Performance Review Board Membership
The USDA just announced the new team members for its Performance Review Boards starting November 18, 2025. These boards help decide how top executives get rated and rewarded, making sure everything’s fair and by the book. If you’re a senior leader at USDA, this update affects how your performance and pay get reviewed.